This study will evaluate the efficacy, safety and tolerability of HS-20093 compared with active surveillance as consolidation therapy after chemoradiotherapy in participants with limited-stage small cell lung cancer.
Have signed Informed Consent Form.
Males or females ≥18 years old.
Patients with limited-stage SCLC who are deemed unsuitable for surgery or decline surgery.
ECOG performance status of 0-1.
Patients with mixed SCLC or NSCLC or sarcoma-like carcinoma, or large cell neuroendocrine carcinoma.
Patients with extensive-stage SCLC.
Disease progression during CRT or before randomization.
For LS-SCLC, prior treatment with or current use of other chemotherapy regimens other than platinum plus etoposide
Hansoh BioMedical R&D Company
Lead sponsor